Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 276–300 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.
· Cell Death Discov · 2024 · PMID 38461159 · validated civic_curation pubmed
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.
· Cell Death Dis · 2021 · PMID 34247201 · validated civic_curation pubmed
Targeting Akt3 signaling in triple-negative breast cancer.
· Cancer Res · 2014 · PMID 24335962 · validated civic_curation pubmed
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
· Mol Cancer Ther · 2012 · PMID 22302096 · validated civic_curation pubmed
Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.
· Cancer · 2012 · PMID 22252991 · validated civic_curation pubmed
Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.
· Mol Carcinog · 2017 · PMID 26894620 · validated civic_curation pubmed
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
· Mol Cancer Res · 2014 · PMID 24296758 · validated civic_curation pubmed

Showing 276–300 of 384 publications

← Previous
1
…
11
12
13
…
16
Next →

Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.

· Cancer Res · 2014 · PMID 24253377 · validated civic_curation pubmed

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

· Mol Cancer Res · 2009 · PMID 19737969 · validated civic_curation pubmed

Michael B et al. J Clin Oncol 2022

· 2022 · PMID 36493333 · validated cbioportal_study pubmed

Miao et al. Science 2019

· 2019 · PMID 29301960 · validated cbioportal_study pubmed

Choueiri et al. Clin Cancer Res. 2016

· 2016 · PMID 27169994 · validated cbioportal_study pubmed

Gerlinger et al. Nat Genet 2014

· 2014 · PMID 24487277 · validated cbioportal_study pubmed

Vasudev, Neeraj S. et al. Clinical Cancer Research, 2023

· 2023 · PMID 36815791 · validated cbioportal_study pubmed

Guda et al. PNAS 2015

· 2015 · PMID 25583493 · validated cbioportal_study pubmed

Vasaikar et al. Cell 2019

· 2019 · PMID 31031003 · validated cbioportal_study pubmed

Roelands et al, Nat Med 2023

· 2023 · PMID 37202560 · validated cbioportal_study pubmed

Li et al. Cancer Cell 2020

· 2020 · PMID 32888432 · validated cbioportal_study pubmed

Giannakis et al. Cell Reports 2016

· 2016 · PMID 27149842 · validated cbioportal_study pubmed

Seshagiri et al. Nature 2012

· 2012 · PMID 22895193 · validated cbioportal_study pubmed

Brannon et al. Genome Biol 2014

· 2014 · PMID 25164765 · validated cbioportal_study pubmed

Yaeger et al. Cancer Discovery 2022

· 2022 · PMID 36355783 · validated cbioportal_study pubmed

TCGA, Nature 2012

· 2012 · PMID 22810696 · validated cbioportal_study pubmed

Mondaca et al. Gastroenterology 2020

· 2020 · PMID 32730818 · validated cbioportal_study pubmed

Gularte-Merida et al. JCO Precis Oncol 2022

· 2022 · PMID 35235413 · validated cbioportal_study pubmed